Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 41: 1605-1613, 1995;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Petersen, N. E.
Right arrow Articles by Kristiansen, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Petersen, N. E.
Right arrow Articles by Kristiansen, K.

Clinical Chemistry, Vol 41, 1605-1613, Copyright © 1995 by American Association for Clinical Chemistry

Improved RNase protection assay for quantifying LDL-receptor mRNA; estimation of analytical imprecision and biological variance in peripheral blood mononuclear cells

NE Petersen, LK Larsen, H Nissen, LG Jensen, A Jensen, P Hyltoft Petersen, , N Gregersen and K Kristiansen
Department of Clinical Biochemistry, Odense University Hospital, Denmark.

We have improved the protocol for RNA quantification by using RNase protection. Instead of precipitation and extraction with phenol and chloroform, we use a faster and more reliable precipitation based on guanidinium thiocyanate (GdSCN). The internal standard is produced by in vitro transcription of a DNA template constructed so as to allow simultaneous detection of the in vitro transcript and the low-density lipoprotein receptor (LDLR) mRNA by use of the same probe and hybridization. Addition of this internal standard at the step for RNA isolation reduced the analytical imprecision from 40.8% to 19.3%. Estimates of the within- and between-subject biological variations of the LDLR mRNA content in peripheral blood mononuclear cells (PBMCs) isolated from healthy volunteers were 21.5% and 13.6%, respectively, and the analytical imprecision was 22.6%. The mean content of LDLR mRNA in PBMCs from healthy individuals was 0.78 copies per cell.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Cancer Res.Home page
D. Generali, S. B. Fox, A. Berruti, J. W. Moore, M. P. Brizzi, N. Patel, G. Allevi, S. Bonardi, S. Aguggini, A. Bersiga, et al.
Regulation of Hepatocyte Growth Factor Activator Inhibitor 2 by Hypoxia in Breast Cancer
Clin. Cancer Res., January 15, 2007; 13(2): 550 - 558.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. Mitsuhashi, S. Tomozawa, K. Endo, and A. Shinagawa
Quantification of mRNA in Whole Blood by Assessing Recovery of RNA and Efficiency of cDNA Synthesis
Clin. Chem., April 1, 2006; 52(4): 634 - 642.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Ameri, C. E. Lewis, M. Raida, H. Sowter, T. Hai, and A. L. Harris
Anoxic induction of ATF-4 through HIF-1-independent pathways of protein stabilization in human cancer cells
Blood, March 1, 2004; 103(5): 1876 - 1882.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
R. Ovstebo, K. B. F. Haug, K. Lande, and P. Kierulf
PCR-based Calibration Curves for Studies of Quantitative Gene Expression in Human Monocytes: Development and Evaluation
Clin. Chem., March 1, 2003; 49(3): 425 - 432.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. J. Turner, J. W. Moore, A. Jones, C. F. Taylor, D. Cuthbert-Heavens, C. Han, R. D. Leek, K. C. Gatter, P. H. Maxwell, P. J. Ratcliffe, et al.
Expression of Hypoxia-inducible Factors in Human Renal Cancer: Relationship to Angiogenesis and to the von Hippel-Lindau Gene Mutation
Cancer Res., May 1, 2002; 62(10): 2957 - 2961.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Blancher, J. W. Moore, N. Robertson, and A. L. Harris
Effects of ras and von Hippel-Lindau (VHL) Gene Mutations on Hypoxia-inducible Factor (HIF)-1{alpha}, HIF-2{alpha}, and Vascular Endothelial Growth Factor Expression and Their Regulation by the Phosphatidylinositol 3'-Kinase/Akt Signaling Pathway
Cancer Res., October 1, 2001; 61(19): 7349 - 7355.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Jones, C. Fujiyama, C. Blanche, J. W. Moore, S. Fuggle, D. Cranston, R. Bicknell, and Adrian. L. Harris
Relation of Vascular Endothelial Growth Factor Production to Expression and Regulation of Hypoxia-inducible Factor-1{{alpha}} and Hypoxia-inducible Factor-2{{alpha}} in Human Bladder Tumors and Cell Lines
Clin. Cancer Res., May 1, 2001; 7(5): 1263 - 1272.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
C. Blancher, J. W. Moore, K. L. Talks, S. Houlbrook, and A. L. Harris
Relationship of Hypoxia-inducible Factor (HIF)-1{{alpha}} and HIF-2{{alpha}} Expression to Vascular Endothelial Growth Factor Induction and Hypoxia Survival in Human Breast Cancer Cell Lines
Cancer Res., December 1, 2000; 60(24): 7106 - 7113.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the American Association for Clinical Chemistry.